Construction to host IBA’s Proteus®ONE system expected to start later this year
Louvain-La-Neuve, Belgium, 09 July 2019 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract and received the first payment for a Proteus®ONE solution with The University of Kansas Health System. The contract includes a plan for a possible extension with a second Proteus®One unit in the future. The proton therapy center will be built at the Main Campus of The University of Kansas Health System in Kansas City, Kansas. Construction is anticipated to begin later this year.
The contract includes a long-term operation and maintenance agreement and the typical end-user price for a Proteus®ONE* solution with a maintenance contract is between EUR 35 and 40 million. IBA will begin to recognize revenue for the contract in the 2019 financial year.
Olivier Legrain, Chief Executive Officer of IBA, commented: “We are delighted to collaborate with The University of Kansas Health System, one of the leading academic medical centers in the US. With a current market share of around 50% in compact proton therapy systems, IBA’s Proteus®ONE solution clearly stands out as the most advanced technology available in the market. In addition, our current research projects aiming at delivering Spot Scanning Proton Arc therapy as well as FLASH therapy dose rates in the near future will keep us ahead of our competitors for the years to come.”
Bob Page, President and chief executive officer of The University of Kansas Health System commented: “We are excited to partner with IBA, the world’s leading proton therapy system provider, to bring proton therapy to Kansas City and the region. IBA’s Proteus® ONE represents one of the most advanced solutions to delivering proton therapy. With the first system in place, and the ability to add a second system in the future, patients will be able to stay closer to home to receive the most advanced cancer care available.
***ENDS***
About Proteus®ONE
Proteus®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus®ONE is smaller, more affordable, easier to install and to operate, making this advanced radiation therapy modality available to more institutions and patients worldwide.
* Proteus®ONE is the brand name of Proteus®235.
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1400 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
About The University of Kansas Health System
The University of Kansas Health System is a premier academic health system, providing a full range of care for the region and the state of Kansas. It includes The University of Kansas Physicians, the largest multispecialty physician group in the region. The health system is affiliated with the University of Kansas Schools of Medicine, Nursing and Health Professions, and their leading-edge research projects. In addition to its main location in Kansas City, the health system includes hospitals and clinics at HaysMed in Hays, St. Francis Campus in Topeka, Great Bend Campus and St. Rose Medical Pavilion in Great Bend, and Pawnee Valley Campus in Larned. Services range from routine primary care to multispecialty care for complex conditions. The health system provides the region’s only nationally verified burn center and nationally verified Level I Trauma Center, as well as a leading transplant program in liver, pancreas, kidney, heart, and blood and marrow. The cancer program is part of The University of Kansas Cancer Center, one of 70 National Cancer Institute-designated cancer centers. The health system’s Kansas City hospital has received Magnet nursing designation three times in a row for the highest level of care. The hospital has also ranked for more than a decade on U.S. News & World Report’s Best Hospitals lists, currently ranking in nine medical and surgical specialties. The health system receives no state or local appropriations, instead relying on operating revenue, bonding authority and philanthropy. For more information, visit kansashealthsystem.com
For further information, please contact:
IBA
Soumya Chandramouli
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com
Thomas Ralet
Head of Corporate Communication
+32 10 475 890
communication@iba-group.com
For media and investor enquiries:
Consilium Strategic Communications
Amber Fennell, Angela Gray, Lizzie Seeley
+44 (0) 20 3709 5700
IBA@consilium-comms.com
Attachment
